The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging Mohammed AlbatanySusan MeakinRobert Bartha PRECLINICAL STUDIES 13 August 2018 Pages: 595 - 601
Hexane partition from Annona crassiflora Mart. promotes cytotoxity and apoptosis on human cervical cancer cell lines Viviane A. O. SilvaAna Laura V. AlvesRui M. Reis PRECLINICAL STUDIES 29 August 2018 Pages: 602 - 615
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma Lei ZhongShu ZhouQian Peng PRECLINICAL STUDIES 31 August 2018 Pages: 616 - 624
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia Muhammed H. RahamanYingyi YuShudong Wang PRECLINICAL STUDIES 08 September 2018 Pages: 625 - 635
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases Hani M. BabikerSara A. ByronMichael S. Gordon PRECLINICAL STUDIES 28 September 2018 Pages: 636 - 645
Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma Peng-jin MeiJin BaiYue-chao Fan PRECLINICAL STUDIES 17 October 2018 Pages: 646 - 657
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors Fen WangJulian MolinaAlex A. Adjei PHASE I STUDIES 31 October 2018 Pages: 658 - 665
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors Xiaofei ZhouSandeepraj PusalkarKarthik Venkatakrishnan PHASE I STUDIES 06 November 2018 Pages: 666 - 673
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors Elena ElezCarlos Gomez-RocaJean-Pierre Delord PHASE I STUDIES 09 November 2018 Pages: 674 - 683
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors Kabir ModyAaron S. MansfieldMitesh Borad PHASE I STUDIES 21 November 2018 Pages: 684 - 692
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer Alexandra LearyChristophe Le TourneauJean-Pierre Delord PHASE I STUDIES Open access 14 December 2018 Pages: 693 - 701
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma Theodoros N. TeknosJ. GreculaP. Savvides PHASE I STUDIES 19 December 2018 Pages: 702 - 710
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers Lisa SeitzLixia JinJoyson Karakunnel PHASE I STUDIES 19 December 2018 Pages: 711 - 721
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors David C. SmithRashmi ChughAnthony Tolcher PHASE I STUDIES Open access 28 December 2018 Pages: 722 - 730
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial Jian-Chun DuanZhi-Jie WangJie Wang PHASE I STUDIES 01 February 2019 Pages: 731 - 737
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors Jeffrey P. SharmanJennifer J. WhelerShadia I. Jalal PHASE II STUDIES Open access 16 April 2019 Pages: 738 - 747
Phase II study of avelumab in multiple relapsed/refractory germ cell cancer M. MegoD. SvetlovskaJ. Mardiak PHASE II STUDIES 01 June 2019 Pages: 748 - 754
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma Hao XieJun YinAlex A. Adjei PHASE II STUDIES 06 June 2019 Pages: 755 - 762
Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis Junho KangChanghoon YooBaek-Yeol Ryoo SHORT REPORT 10 December 2018 Pages: 763 - 770
Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapy Maurizio VialeRita TostoGraziella Vecchio SHORT REPORT 17 December 2018 Pages: 771 - 778
Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases Rejitha SurajJasim Al-RawiChristopher Bradley SHORT REPORT 10 January 2019 Pages: 779 - 783
An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent Wang YanChen XiangyuXu Feng SHORT REPORT 11 February 2019 Pages: 784 - 790
Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report Kazunori HondaShigenori KadowakiKei Muro SHORT REPORT 21 February 2019 Pages: 791 - 795
Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL Jung Jin HwangYong Sook KimChoung-Soo Kim Correction 02 April 2019 Pages: 796 - 796
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma Glen J. WeissLisa BlaydornVivek Khemka Correction 24 April 2019 Pages: 797 - 797